Recent News

By Category: Research

Bavarian Nordic’s IMVANEX(r) Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities

(TheWallStreetJournal) Bavarian Nordic A/S (OMX:BAVA) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for IMVANEX(r) for active immunization against smallpox disease for the general adult population, including people with immunodeficiencies (people diagnosed with Read More »

June 3, 2013
| Filed under Europe, North America, Agents & Toxins, Countermeasures, International, Public Health, and Research
Share

Notable Contracts: DTRA Award to Institute for Systems Biology

(GlobalBiodefense) The Department of Defense this week announced a notable contract award related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense: Institute for Systems Biology, Seattle, Wash., is being awarded a $7,665,557 cost-type contract for research into pre-symptomatic detection of post-operative Read More »

June 3, 2013
| Filed under North America, Biological Weapons, Countermeasures, Policy & Initiatives, and Research
Share

Double dose of antiviral drug offers no added benefit in severe influenza

(EurekAlert) Giving double doses of the antiviral drug oseltamivir, or Tamiflu, offers no clinical or virological advantages over a standard dose for patients admitted to hospital with severe influenza infection, according to a randomised trial published today and funded by the Wellcome Trust, US National Institute of Allergy and Infectious Diseases and the Singapore National Read More »

May 31, 2013
| Filed under North America, Agents & Toxins, Public Health, and Research
Share

FDA Lifts Clinical Hold On PharmAthene’s SparVax(R) Anthrax Vaccine Program

(TheWallStreetJournal) PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on a proposed Phase II study of SparVax(R) , a next generation recombinant anthrax vaccine. “We are very pleased by the Read More »

May 31, 2013
| Filed under North America, Agents & Toxins, Biological Weapons, Bioterrorism, Countermeasures, Public Health, and Research
Share

Experts Call For Increased Monitoring Of Drug Resistant Bird Flu

(MedicalNewsToday) Drug resistance was detected in more than half of human H5N1 viruses in a new study published in the journal Antiviral Research, causing experts to call for increased monitoring of the bird flu. Highly pathogenic influenza viruses (H5N1) mostly impact birds but can sometimes cross the species barrier and infect people. H5N1 flu outbreaks Read More »